Community Practice Connections: 1st Annual European Symposium on Lung Cancers
WebcastFaculty
OVERVIEW
Community Practice Connections: 1st Annual European Symposium on Lung Cancers is organized by Physicians Education Resource, LLC (PER) and will be held during Aug 31, 2017 - Aug 31, 2018.
The target audience for this medical event is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other healthcare professionals involved in the treatment and management of patients with lung cancer. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Overview :
Community Practice Connections: 1st Annual European Symposium on Lung Cancers™ features a summary of clinical evidence guiding best practices in the treatment of patients with non–small cell lung cancer (NSCLC), including recent developments with targeted agents and immunotherapy. Interactive clinical vignettes are followed by short video interviews with internationally renowned experts in the management of patients with NSCLC. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting by medical professionals engaged in the care of patients with NSCLC.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
• Utilize tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced NSCLC
• Discuss current and emerging roles for single-agent and combination immunotherapeutic strategies in the management of advanced lung cancers
• Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
• Assess evolving data sets concerning the use of ALK inhibition in frontline and subsequent lines of care in advanced NSCLC
• Discuss emerging targeted approaches for oncogenic drivers in NSCLC beyond EGFR and ALK
• Identify approaches to address treatment-related toxicities in patients with lung cancer
• Integrate personalized approaches to manage challenging cases in advanced lung cancer settings
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other healthcare professionals involved in the treatment and management of patients with lung cancer. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Overview :
Community Practice Connections: 1st Annual European Symposium on Lung Cancers™ features a summary of clinical evidence guiding best practices in the treatment of patients with non–small cell lung cancer (NSCLC), including recent developments with targeted agents and immunotherapy. Interactive clinical vignettes are followed by short video interviews with internationally renowned experts in the management of patients with NSCLC. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting by medical professionals engaged in the care of patients with NSCLC.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
• Utilize tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced NSCLC
• Discuss current and emerging roles for single-agent and combination immunotherapeutic strategies in the management of advanced lung cancers
• Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
• Assess evolving data sets concerning the use of ALK inhibition in frontline and subsequent lines of care in advanced NSCLC
• Discuss emerging targeted approaches for oncogenic drivers in NSCLC beyond EGFR and ALK
• Identify approaches to address treatment-related toxicities in patients with lung cancer
• Integrate personalized approaches to manage challenging cases in advanced lung cancer settings
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links